Paclitaxel
Showing 1 - 25 of 5,234
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin
Recruiting
- Gastric Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Oct 22, 2023
Adenocarcinoma of Stomach Trial in Shanghai (Gentuximab Injection, Gentuximab Injection Placebo)
Recruiting
- Adenocarcinoma of Stomach
- Gentuximab Injection
- Gentuximab Injection Placebo
-
Shanghai, Shanghai, ChinaShanghai Dongfang Hospital
Jun 16, 2023
Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound
Active, not recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Albumin-bound Paclitaxel
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023
Gastric or Esophagogastric Junction Adenocarcinoma Trial (nimotuzumab plus paclitaxel, plus paclitaxel)
Not yet recruiting
- Gastric or Esophagogastric Junction Adenocarcinoma
- nimotuzumab plus paclitaxel
- placebo plus paclitaxel
- (no location specified)
Aug 3, 2023
Chemo-induced Peripheral Neuropathy Trial (Curcumin, Paclitaxel)
Not yet recruiting
- Chemotherapy-induced Peripheral Neuropathy
- Curcumin
- Paclitaxel
- (no location specified)
Jul 21, 2023
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin
Recruiting
- Gastric Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Oct 22, 2023
Coronary Artery Disease Trial in Meizhou (Paclitaxel-Coated Coronary Balloon Catheters, Paclitaxel-Releasing Coronary Balloon
Not yet recruiting
- Coronary Artery Disease
- Paclitaxel-Coated Coronary Balloon Catheters
- Paclitaxel-Releasing Coronary Balloon Catheters
-
Meizhou, Guangdong, ChinaMeizhou People's Hospital (Huangtang Hospital, Meizhou Academy o
Aug 31, 2023
Locally Advanced Cervical Cancer Trial in Xi'an (Zimberelimab, Albumin-bound Paclitaxel, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Zimberelimab
- +2 more
-
Xi'an, Shaanxi, ChinaHongxi Zhao
Sep 20, 2023
Extensive Stage Small Cell Lung Cancer Trial (hSTC810 400 mg + Paclitaxel, hSTC810 800 mg + Paclitaxel)
Not yet recruiting
- Extensive Stage Small Cell Lung Cancer
- hSTC810 400 mg + Paclitaxel
- hSTC810 800 mg + Paclitaxel
- (no location specified)
Aug 24, 2023
Metastatic Pancreatic Cancer, Adenocarcinoma of the Pancreas Trial in Weiden (nab-paclitaxel and gemcitabine, gemcitabine mono
Completed
- Metastatic Pancreatic Cancer
- Adenocarcinoma of the Pancreas
- nab-paclitaxel and gemcitabine
- gemcitabine mono and nab-paclitaxel and gemcitabine
-
Weiden, GermanyKliniken Nordoberpfalz AG, Klinikum Weiden
Nov 21, 2022
Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma Trial in United States (Laboratory
Active, not recruiting
- Locally Advanced Breast Carcinoma
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +3 more
Jan 31, 2023
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung
Not yet recruiting
- Advanced Non-squamous Non-small-cell Lung Cancer
- +2 more
- pembrolizumab
- +2 more
-
Beijing, Beijing, ChinaPeking University First Hospital Ethics Committee
Sep 10, 2023
Gastroesophageal Adenocarcinoma Trial (Paclitaxel, Ramucirumab, Zanidatamab)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- Paclitaxel
- +2 more
- (no location specified)
Sep 12, 2023
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Withdrawn
- Anatomic Stage III Breast Cancer AJCC v8
- +11 more
- Atezolizumab
- +2 more
- (no location specified)
Jan 5, 2023
Early-stage Breast Cancer Trial in Ottawa (Granulocyte Colony-Stimulating Factor (G-CSF), Omission of Granulocyte
Not yet recruiting
- Early-stage Breast Cancer
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
-
Ottawa, Ontario, CanadaThe Ottawa Hospital Cancer Centre
Feb 22, 2023
Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))
Not yet recruiting
- Gastric Adenocarcinoma
- cadonilimab combined +paclitaxel (albumin-bound)
- (no location specified)
Nov 1, 2023
Endometrial Carcinoma Trial in Sohag (Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin)
Not yet recruiting
- Endometrial Carcinoma
-
Sohag, EgyptSohag university Hospital
Oct 25, 2023
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) Trial in Tianjin (Serplulimab+Paclitaxel+Apatinib,
Recruiting
- Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jul 5, 2023
Urethral Stricture, Male Trial in Cairo (Ho-YAG Laser Visual internal urethrotomy, Ho-YAG Laser Visual internal urethrotomy
Completed
- Urethral Stricture, Male
- Ho-YAG Laser Visual internal urethrotomy
- Ho-YAG Laser Visual internal urethrotomy combined with intralesional submucosal injection of Paclitaxel
-
Cairo, EgyptDemerdash hospital, Faculty of medicine, Ain Shams University
Nov 7, 2023
Breast Carcinoma Trial in Houston (biological, drug, other)
Not yet recruiting
- Breast Carcinoma
- eftilagimod alpha
- +2 more
-
Houston, TexasOncology Consultants
Feb 17, 2023
Central Airway Obstruction Trial in Tbilisi (Paclitaxel-Coated Pulmonary Balloon Catheter)
Recruiting
- Central Airway Obstruction
- Paclitaxel-Coated Pulmonary Balloon Catheter
-
Tbilisi, GeorgiaTbilisi State Medical University
May 31, 2023
PDAC - Pancreatic Ductal Adenocarcinoma Trial (Combination of sitagliptin+ gemcitabine + nab-paclitaxel)
Not yet recruiting
- PDAC - Pancreatic Ductal Adenocarcinoma
- Combination of sitagliptin+ gemcitabine + nab-paclitaxel
- (no location specified)
Jul 9, 2023
Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)
Recruiting
- Locally Advanced Breast Cancer
- Chemotherapy Effect
- inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
-
Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Feb 28, 2023
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 Trial
Recruiting
- Borderline Resectable Pancreatic Adenocarcinoma
- +5 more
- Durvalumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022